# US 2026/0085057 A1 · Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085057 A1
- Document ID: US20260085057A1
- Status: Published application
- Kind: A1
- Application number: 19/353,722
- Filed: 2025-10-09
- Published: 2026-03-26
- Earliest claimed: 2016-06-01
- Assignees: Bayer Pharma Aktiengesellschaft
- Applicants: Bayer Pharma Aktiengesellschaft
- Inventors: Gerald BEDDIES; Adrian FOSTER; Ulrich BOTHE; Nicole SCHMIDT; Ulf BOEMER; Reinhard NUBBEMEYER; Maria De Lourdes MOTTIER
- Web page: https://patentgrep.com/patent/US20260085057A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/04: for throat disorders
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to the use of substituted indazoles for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially for treatment and/or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals.

## Claims

### Claim 1

A method for the treatment, and/or prophylaxis of inflammatory disease in a dog comprising administering to the dog a compound of the general formula (I)
wherein
R1 is C1-C6-alkyl, wherein the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen, hydroxyl, an unsubstituted or mono- or poly-halogen-substituted C3-C6-cycloalkyl, or an R6, R7SO2, R7SO or R8O group, or a group selected from:
wherein * represents the bonding site of the group to the rest of the molecule;
R2 and R3 always have the same definition and are either hydrogen or C1-C6-alkyl;
R4 is halogen, cyano, an unsubstituted or a singly or multiply, identically or differently substituted C1-C6-alkyl or an unsubstituted or a singly or multiply, identically or differently substituted C3-C6-cycloalkyl, and the substituents are selected from the group of halogen and hydroxyl;
R5 is hydrogen, halogen or an unsubstituted or mono- or poly-halogen-substituted C1-C6-alkyl;
R6 is an unsubstituted or mono- or di-methyl-substituted monocyclic saturated heterocycle having 4 to 6 ring atoms, which contains a heteroatom or a heterogroup from the group of O, S, SO and SO2;
R7 is C1-C6-alkyl, wherein the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen, hydroxyl or C3-C6-cycloalkyl;
or R7 is C3-C6-cycloalkyl;
R8 is C1-C6-alkyl, wherein the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen;
or a diastereomer, an enantiomer, a metabolite, a salt, a solvate, a solvate of the salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein
R1 is C1-C6-alkyl, wherein the C1-C6-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by fluorine, hydroxyl or an R6, R7SO2, R7SO or R8O group;
R2 and R3 always have the same definition and are either hydrogen or C1-C3-alkyl;
R4 is halogen, cyano or C1-C3-alkyl, wherein the C1-C3-alkyl group is unsubstituted or mono- or polysubstituted identically or differently by halogen or hydroxyl;
R5 is hydrogen, fluorine, chlorine or C1-C3-alkyl;
R6 is oxetanyl or tetrahydrofuranyl;
R7 is C1-C4-alkyl, wherein the C1-C4-alkyl group is unsubstituted or monosubstituted by hydroxyl or by cyclopropyl or substituted by three fluorine atoms; and
R8 is an unsubstituted C1-C4-alkyl group or a tri-fluorine-substituted C1-C4-alkyl group.

### Claim 3 (depends on 1)

The method of claim 1, wherein R4 is difluoromethyl, trifluoromethyl or methyl.

### Claim 4 (depends on 1)

The method of claim 1, wherein R5 is hydrogen or fluorine.

### Claim 5 (depends on 1)

The method of claim 1, wherein R2 and R3 are either hydrogen or methyl.

### Claim 6 (depends on 2)

The method of claim 2, wherein
R1 is C2-C6-alkyl, wherein the C2-C6-alkyl group is unsubstituted, or the C2-C6-alkyl group is mono-, di- or tri-fluorine-substituted or the C2-C6-alkyl group is monosubstituted by hydroxyl, R6, R7SO2, or R8O, or R1 is an oxetanyl-substituted C1-C3-alkyl group;
R2 and R3 always have the same definition and are either hydrogen or methyl;
R4 is an unsubstituted or mono- or poly-halogen-substituted C1-C3-alkyl group or a C1-C3-alkyl group substituted by one hydroxyl group or a C1-C3-alkyl group substituted by one hydroxyl group and three fluorine atoms;
R5 is hydrogen, fluorine or C1-C3-alkyl;
R7 is C1-C3-alkyl; and
R8 is C1-C4-alkyl, wherein the C1-C4-alkyl group is unsubstituted or mono-, di- or tri-fluorine-substituted.

### Claim 7 (depends on 6)

The method of claim 6, wherein
R1 is a C2-C5-alkyl group substituted by hydroxyl or C1-C3-alkoxy or trifluoromethoxy or 2,2,2-trifluoroethoxy or trifluoromethyl or is a methyl-SO2-substituted C2-C4-alkyl group or is an oxetan-3-yl-substituted C1-C2-alkyl group;
R2 and R3 always have the same definition and are hydrogen or methyl;
R4 is methyl, ethyl, trifluoro-C1-C3-alkyl, difluoro-C1-C3-alkyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropan-2-yl and 2,2,2-trifluoro-1-hydroxyethyl; and
R5 is hydrogen, fluorine or methyl.

### Claim 8 (depends on 7)

The method of claim 7, wherein
R1 is 4,4,4-trifluorobutyl, 3-hydroxy-3-methylbutyl, 3-hydroxybutyl, 3-methoxypropyl, 3-hydroxypropyl, 3-hydroxy-2-methylpropyl, 3-hydroxy-2,2-dimethylpropyl, 3-trifluoromethoxypropyl, 2-methoxyethyl, 2-hydroxyethyl, 2-(methylsulphonyl)ethyl or 3-(methylsulphonyl)propyl;
R2 and R3 are methyl or hydrogen;
R4 is difluoromethyl, trifluoromethyl or methyl; and
R5 is hydrogen or fluorine.

### Claim 9 (depends on 8)

The method of claim 8, wherein
R1 is 3-hydroxy-3-methylbutyl, 3-hydroxybutyl, 3-hydroxy-2-methylpropyl, 3-hydroxy-2,2-dimethylpropyl, 3-(methylsulphonyl)propyl or 2-(methylsulphonyl)ethyl;
R2 and R3 are methyl;
R4 is difluoromethyl or trifluoromethyl; and
R5 is hydrogen.

### Claim 10 (depends on 8)

The method of claim 8, wherein
R1 is 3-hydroxy-3-methylbutyl, 3-hydroxybutyl, 3-hydroxy-2-methylpropyl, 3-hydroxy-2,2-dimethylpropyl, 3-(methylsulphonyl)propyl or 2-(methylsulphonyl)ethyl;
R2 and R3 are methyl;
R4 is methyl; and
R5 is fluorine, wherein R5 is in the ortho position to R4.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:
1) N-[6-(2-Hydroxypropan-2-yl)-2-(2-methoxyethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
2) N-[6-(Hydroxymethyl)-2-(2-methoxyethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
3) N-[6-(2-Hydroxypropan-2-yl)-2-(3-methoxypropyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
4) N-[6-(Hydroxymethyl)-2-(3-methoxypropyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
5) N-[2-(2-Hydroxyethyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
6) N-[6-(2-Hydroxypropan-2-yl)-2-(3-hydroxypropyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
7) N-[2-(2-Hydroxyethyl)-6-(hydroxymethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
8) N-[6-(2-Hydroxypropan-2-yl)-2-(oxetan-3-ylmethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
9) N-[6-(Hydroxymethyl)-2-(oxetan-3-ylmethyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
10) N-{6-(2-Hydroxypropan-2-yl)-2-[3-(methylsulphonyl)propyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;
11) N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
12) N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;
13) 6-(Difluoromethyl)-N-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]pyridine-2-carboxamide;
14) 6-(Difluoromethyl)-N-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}pyridine-2-carboxamide;
15) 6-(Difluoromethyl)-N-[6-(2-hydroxypropan-2-yl)-2-(3-hydroxypropyl)-2H-indazol-5-yl]pyridine-2-carboxamide;
16) N-[6-(2-Hydroxypropan-2-yl)-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;
17) N-{6-(2-Hydroxypropan-2-yl)-2-[3-(trifluoromethoxy)propyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;
18) N-{6-(2-Hydroxypropan-2-yl)-2-[3-(2,2,2-trifluoroethoxy)propyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide;
19) 5-Fluoro-N-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-methylpyridine-2-carboxamide;
20) N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-methylpyridine-2-carboxamide;
21) 6-(2-Hydroxypropan-2-yl)-N-[6-(2-hydroxypropan-2-yl)-2-(4,4,4-trifluorobutyl)-2H-indazol-5-yl]pyridine-2-carboxamide; and
22) N-{2-[2-(1-Hydroxycyclopropyl)ethyl]-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide; or
a diastereomer, an enantiomer, a metabolite, a salt, a solvate, and a solvate of the salt thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the inflammatory disease is atopic dermatitis or inflammatory pain.

### Claim 13 (depends on 1)

The method of claim 1, wherein the inflammatory disease is Canine Atopic Dermatitis.

### Claim 14 (depends on 1)

The method of claim 1, wherein the inflammatory disease is inflammatory pain.

### Claim 15 (depends on 1)

A method for the treatment and/or prophylaxis of inflammatory disease in a dog, wherein the method comprises administering to the dog, a pharmaceutical composition comprising the compound of claim 1 and an inert, non-toxic, pharmaceutically suitable excipient.

### Claim 16 (depends on 15)

The method of claim 15, wherein the inflammatory disease is atopic dermatitis or inflammatory pain.

### Claim 17 (depends on 17)

The method of claim 17, wherein the inflammatory disease is Canine Atopic Dermatitis.

### Claim 18 (depends on 17)

The method of claim 17, wherein the inflammatory disease is inflammatory pain.

### Claim 19 (depends on 1)

The method of claim 1, wherein an effective amount of the compound is administered to a dog in need thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the effective amount is about 10 to 20 mg/kg body weight of the dog.

### Claim 21 (depends on 1)

The method of claim 1, wherein the administration is oral.

### Claim 22 (depends on 1)

The method of claim 1, wherein the administration is once daily.
